Medication info
Glywon Tablet 4 mg (Glimepiride)

Glywon Tablet 4 mg (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›4mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Blue or light blue oblong tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200802788 · Notified 2008.03.13 · Insurance code 640004310

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received drug therapy, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control with doses increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combining this medication with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this medication needed may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral glucose-lowering agent to this medication There is no exact dose equivalence between this medication and other oral glucose-lowering agents. When switching from another oral glucose-lowering agent to this medication, it is recommended to follow the directions given under Initial dose. That is, start at 1 mg once daily, and adjust the dose at 1 ~ 2-week intervals. The potency and duration of action of the previously administered medication should be considered. 4) Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this medication, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after it has been successfully treated initially during administration of sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy of this medication with insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medication once daily with the first meal, and initiate insulin at a low dose, increasing it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medication, addition of metformin may be considered. Clinical information has been published on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medication is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medication. However, efforts should be made to determine the minimum effective dose of each medication for blood glucose control. There is a risk of hypoglycemia when this medication is administered with metformin, and the risk may increase. Appropriate caution should be exercised.

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

View approved original text

This medication is used alongside diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be used alone or added when blood sugar control is inadequate with oral hypoglycemics or insulin. Additionally, when blood sugar control is insufficient with sulfonylureas or metformin monotherapy, it may be combined with metformin to enhance effectiveness. This helps improve blood sugar control and aids in patient health management.

How to take

Adult dose

1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received drug therapy, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control with doses increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combining this medication with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the amount of this medication needed may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral glucose-lowering agent to this medication There is no exact dose equivalence between this medication and other oral glucose-lowering agents. When switching from another oral glucose-lowering agent to this medication, it is recommended to follow the directions given under Initial dose. That is, start at 1 mg once daily, and adjust the dose at 1 ~ 2-week intervals. The potency and duration of action of the previously administered medication should be considered. 4) Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this medication, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after it has been successfully treated initially during administration of sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy of this medication with insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medication once daily with the first meal, and initiate insulin at a low dose, increasing it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medication, addition of metformin may be considered. Clinical information has been published on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medication is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medication. However, efforts should be made to determine the minimum effective dose of each medication for blood glucose control. There is a risk of hypoglycemia when this medication is administered with metformin, and the risk may increase. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or in a comatose state. Patients with a history of allergic reactions to this medication, its components, or sulfonylureas should also avoid use. There is no experience using this medication in patients with severely impaired liver or kidney function; switching to insulin therapy is recommended in such cases. Women who are pregnant or may become pregnant, as well as nursing mothers, should avoid this medication for safety. Patients with severe infections, those undergoing surgery, or patients with severe trauma may require insulin therapy and should avoid this medication. If gastrointestinal disturbances such as diarrhea or vomiting occur, caution should be exercised due to the risk of hypoglycemia from inadequate food absorption. During the first week of taking this medication, the risk of hypoglycemia is heightened, so blood glucose levels should be closely monitored. Especially in the elderly, those with poor nutritional status or irregular eating habits, or individuals who consume alcohol frequently, the risk of hypoglycemia increases. Caution is also necessary when there is an imbalance between exercise and carbohydrate intake or when eating patterns change. Patients with weak liver or kidney function, those with other endocrine disorders, or in cases of overdose also face increased risk of hypoglycemia. Interactions with other medications may affect blood sugar control, so it is essential to consult a doctor or pharmacist. This medication has the effect of lowering blood sugar, which can lead to the appearance of hypoglycemia symptoms, including headache, severe hunger, nausea, fatigue, drowsiness, confusion, and decreased consciousness. Hypoglycemia should be treated promptly by consuming sugar, and severe symptoms require immediate medical attention. Additionally, while taking this medication, temporary blurred vision, digestive symptoms, liver function abnormalities, blood abnormalities, and allergic reactions may occur, necessitating caution. If allergic symptoms such as hives or difficulty breathing appear, inform a doctor immediately. This medication should be taken regularly for blood sugar control, and dietary and exercise therapies should be accompanied. In case of hypoglycemia, quickly consuming sugar is important, as artificial sweeteners are not effective for hypoglycemia treatment. In situations of severe stress, surgery, or infections, blood sugar control may become difficult, so temporary switching to insulin therapy may be necessary. When used in combination with other medications, this medication may influence blood sugar control, so all medications being taken should be communicated to healthcare providers, and attention should be given to drug interactions. Careful monitoring is especially required when taken with beta-blockers, certain antibiotics, or steroids. Women who are pregnant or breastfeeding should not use this medication as it may affect the fetus or newborn, and insulin therapy should be considered if necessary. The safety and efficacy of this medication have not been adequately established in children and adolescents under 18 years of age. In the elderly, there may be a reduction in kidney function, so dose adjustments should be made cautiously. In cases of overdose, severe hypoglycemia may occur, requiring immediate medical attention and appropriate treatment; if hypoglycemia symptoms appear, sugar should be consumed quickly. This medication should be stored out of reach of children and maintained in its original container to preserve its quality.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disorders, anxiety, aggression, decreased concentration, decreased agility or activity, depression, confusion, language impairment, aphasia, visual impairment, tremor, partial paralysis, sensory abnormalities, dizziness, weakness, loss of self-control, temporary mental confusion, convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, deep vein thrombosis, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, biliary secretion disorder, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, neutropenia, agranulocytosis, pancytopenia, itching, hives, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, phototoxic skin reactions, decreased serum sodium concentration, taste disturbance, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, dyspepsia, facial swelling, erectile dysfunction, facial flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture exposure. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature. Proper storage helps maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Blue or light blue oblong tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.